Andreas Mantoulidis
Company: Boehringer Ingelheim
Job title: Head of Medicinal Chemistry Lab
Seminars:
Targeting KRAS Mutations Beyond G12C: Advancing ACBI3 for Comprehensive KRAS Degradation and Tumour Regression 1:45 pm
Addressing the challenge of undruggable KRAS mutants and secondary mutations by developing ACBI3 as a next-generation therapeutic targeting a broader range of KRAS variants Leveraging a fragment-first approach and structure-guided optimization to refine ACBI3 (a compound developed collaboratively by Boehringer Ingelheim and Prof. Alessio Ciulli’s group) to enhance its biophysical properties and therapeutic potential Demonstrating…Read more
day: Day 1, Track 2, PM
Chair’s Closing Remarks 5:15 pm
day: Day 1, PM